Lebrikizumab-Treated Patients With Atopic Dermatitis Had No Increase in Treatment-Emergent Adverse Events of Facial, Head, and Neck Erythema Compared to Placebo. J of Skin 2023, 7 (6), s272. https://doi.org/10.25251/skin.7.supp.272.